A biotechnology company, Nutra Pharma Corporation (OTCQB:
NPHC) focuses on acquiring, licensing, and commercializing pharmaceutical
products and technologies. The company concentrates on preventing and treating
neurological disorders, cancer, and autoimmune and infectious diseases.
Currently, Nutra Pharma offers Nyloxin® and Nyloxin® Extra Strength, the only
non-narcotic and non-addictive treatments for severe pain that are sold
over-the-counter. The company also markets Pet Pain-Away, an over-the-counter pain
reliever for beloved pets. Furthermore, its multiple sclerosis and HIV
applications are ready to move into phase II clinical trials. Through its two
wholly-owned subsidiaries, Designer Diagnostics and ReceptoPharm, Nutra Pharma
has already been able to contribute to the biopharmaceutical field in
tremendous ways.
ReceptoPharm, the “drug discovery arm” for Nutra Pharma,
develops therapeutic protein products that help prevent and treat viral,
autoimmune, and neurological diseases in humans. For these products, the
company focuses on receptor-binding proteins found in nature, specifically
cobra venom. The two leading products created by ReceptoPharm are RPI-MN and
RPI-78M. The first hinders neurological damaging viruses like encephalitis and
HIV. The second treats neurological disorders like multiple sclerosis and
adrenomyeloneuropathy. Both of these products are easily administered,
stabilized, and cause no severe side effects.
Established in 2005, Designer Diagnostics develops and
markets test kits that can identify harmful disease-causing bacteria quickly.
This early detection allows doctors to administer treatments immediately to
prevent the spreading of disease. The company’s diagnostic tests can detect
harmful nontuberculous mycobacteria, which can lead to tuberculosis, nocardia,
pseudomonas, and mycobacterium avium complex. Fortunately, these tests can
detect diseases in less than a week, have a long shelf life, and can be stored
in almost any environment. Plus, they are cost-effective and can integrate
easily with any laboratory, which makes prevention both feasible and
accessible.
Nutra Pharma, backed by its subsidiaries, aims to deliver
bio-pharmaceutical breakthroughs that proactively increase the quality of life
of people with debilitating diseases. By continuing its business model of
acquiring biotechnological companies with similar goals and interests, the
company stands to make an enormous impact in the pharmaceutical industry.
For more information on the company, visit
www.NutraPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment